Formosa Laboratories Past Earnings Performance
Past criteria checks 4/6
Formosa Laboratories's earnings have been declining at an average annual rate of -7.4%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 11.5% per year. Formosa Laboratories's return on equity is 2.9%, and it has net margins of 8.6%.
Key information
-7.4%
Earnings growth rate
-9.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 11.5% |
| Return on equity | 2.9% |
| Net Margin | 8.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Formosa Laboratories, Inc. (TWSE:4746)
Sep 20
Investors Can Find Comfort In Formosa Laboratories' (TWSE:4746) Earnings Quality
May 22Benign Growth For Formosa Laboratories, Inc. (TWSE:4746) Underpins Its Share Price
Apr 19Here's Why Formosa Laboratories (TPE:4746) Has A Meaningful Debt Burden
Apr 19Does Formosa Laboratories, Inc.'s (TPE:4746) Weak Fundamentals Mean A Downturn In Its Stock Should Be Expected?
Mar 16What Type Of Returns Would Formosa Laboratories'(TPE:4746) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Feb 08Formosa Laboratories (TPE:4746) Is Making Moderate Use Of Debt
Jan 11
Formosa Laboratories's (TPE:4746) Earnings Are Growing But Is There More To The Story?
Dec 13Revenue & Expenses Breakdown
How Formosa Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 4,592 | 393 | 501 | 812 |
| 30 Jun 24 | 4,690 | 256 | 499 | 842 |
| 31 Mar 24 | 4,563 | 55 | 480 | 845 |
| 31 Dec 23 | 4,360 | 126 | 406 | 842 |
| 30 Sep 23 | 4,216 | 270 | 464 | 836 |
| 30 Jun 23 | 4,111 | 876 | 464 | 791 |
| 31 Mar 23 | 3,863 | 785 | 417 | 782 |
| 31 Dec 22 | 3,766 | 409 | 450 | 777 |
| 30 Sep 22 | 3,586 | -94 | 395 | 747 |
| 30 Jun 22 | 3,252 | -970 | 354 | 763 |
| 31 Mar 22 | 3,241 | -217 | 396 | 759 |
| 31 Dec 21 | 3,142 | 1,249 | 439 | 700 |
| 30 Sep 21 | 3,064 | 1,293 | 397 | 638 |
| 30 Jun 21 | 3,189 | 1,778 | 415 | 580 |
| 31 Mar 21 | 3,149 | 1,568 | 412 | 559 |
| 31 Dec 20 | 3,075 | 400 | 369 | 548 |
| 30 Sep 20 | 2,987 | 460 | 395 | 547 |
| 30 Jun 20 | 2,962 | 531 | 387 | 514 |
| 31 Mar 20 | 2,768 | -122 | 344 | 457 |
| 31 Dec 19 | 2,760 | 12 | 354 | 446 |
| 30 Sep 19 | 2,735 | 188 | 365 | 461 |
| 30 Jun 19 | 2,630 | -108 | 395 | 449 |
| 31 Mar 19 | 2,729 | 38 | 408 | 467 |
| 31 Dec 18 | 2,688 | 177 | 395 | 459 |
| 30 Sep 18 | 2,659 | 103 | 390 | 420 |
| 30 Jun 18 | 2,600 | 266 | 344 | 422 |
| 31 Mar 18 | 2,575 | 358 | 347 | 358 |
| 31 Dec 17 | 2,539 | 239 | 333 | 295 |
| 30 Sep 17 | 2,651 | 347 | 329 | 289 |
| 30 Jun 17 | 2,793 | 404 | 335 | 261 |
| 31 Mar 17 | 3,022 | 431 | 323 | 260 |
| 31 Dec 16 | 3,189 | 483 | 322 | 272 |
| 30 Sep 16 | 3,280 | 457 | 320 | 270 |
| 30 Jun 16 | 3,225 | 474 | 314 | 247 |
| 31 Mar 16 | 2,813 | 345 | 282 | 233 |
| 31 Dec 15 | 2,597 | 282 | 271 | 209 |
| 30 Sep 15 | 2,252 | 231 | 235 | 192 |
| 30 Jun 15 | 2,115 | 206 | 232 | 196 |
| 31 Mar 15 | 2,416 | 248 | 241 | 187 |
| 31 Dec 14 | 2,496 | 262 | 233 | 180 |
| 30 Sep 14 | 2,710 | 252 | 244 | 187 |
| 30 Jun 14 | 2,852 | 207 | 231 | 198 |
| 31 Mar 14 | 2,845 | 150 | 228 | 199 |
| 31 Dec 13 | 2,474 | -69 | 220 | 194 |
Quality Earnings: 4746 has high quality earnings.
Growing Profit Margin: 4746's current net profit margins (8.6%) are higher than last year (6.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4746's earnings have declined by 7.4% per year over the past 5 years.
Accelerating Growth: 4746's earnings growth over the past year (45.6%) exceeds its 5-year average (-7.4% per year).
Earnings vs Industry: 4746 earnings growth over the past year (45.6%) exceeded the Pharmaceuticals industry 12.3%.
Return on Equity
High ROE: 4746's Return on Equity (2.9%) is considered low.